Key result
Src tyrosine kinase mediates isoproterenol-induced cardiac hypertrophy, fibrosis, and inflammation via the β-AR/Src/ERK pathway.
Why the study?
The molecular mechanisms governing beta-adrenergic receptor-induced cardiac remodeling remain largely unresolved.
Does Src tyrosine kinase mediate beta-adrenergic receptor-induced cardiac remodeling?
Does Src tyrosine kinase mediate beta-adrenergic receptor-induced cardiac remodeling?
Src tyrosine kinase is a key mediator of beta-adrenergic receptor-induced cardiac remodeling via the ERK1/2 pathway, highlighting it as a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
Src inhibition merits testing in β-AR remodeling models; leaves open translation to human HF therapy.
Cardiac remodeling serves as the underlying pathological basis for numerous cardiovascular diseases and represents a pivotal stage for intervention. The excessive activation of β-adrenergic receptors (β-ARs) assumes a crucial role in cardiac remodeling. Nonetheless, the underlying molecular mechanisms governing β-AR-induced cardiac remodeling remain largely unresolved. In the present study, we identified Src tyrosine kinase as a key player in the cardiac remodeling triggered by excessive β-AR activation. Our findings demonstrated that Src mediates isoproterenol (ISO)-induced cardiac hypertrophy, fibrosis, and inflammation in vivo. Furthermore, Src facilitates β-AR-mediated proliferation and transdifferentiation of cardiac fibroblasts, and hypertrophy and cardiomyocytes in vitro. Subsequent investigations have substantiated that Src mediates β-AR induced the extracellular signal-regulated protein kinase (ERK1/2) signaling pathway activated by β-AR. Our research presents compelling evidence that Src promotes β-AR-induced cardiac remodeling in both in vivo and in vitro settings. It establishes the promoting effect of the β-AR/Src/ERK signaling pathway on overall cardiac remodeling in cardiac fibroblasts and underscores the potential of Src as a therapeutic target for cardiac remodeling.
No takes yet. Share an insight, caveat, or question.
Li et al. (2023) studied Cardiac remodeling. Isoproterenol (inducer) / Src tyrosine kinase (target) was evaluated on Cardiac hypertrophy, fibrosis, and inflammation. Src tyrosine kinase mediates isoproterenol-induced cardiac hypertrophy, fibrosis, and inflammation via the β-AR/Src/ERK signaling pathway in vivo and in vitro.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: